Atai Beckley N.V.

AtaiBeckley is a clinical-stage biopharmaceutical company focused on the research and development of mental health treatments, including therapies for treatment-resistant depression, alcohol use disorder, schizophrenia-related cognitive impairment, and social anxiety disorder. The company's pipeline consists of six primary programs in clinical development and two in preclinical stages. Lead candidates include BPL-003, an intranasal mebufotenin formulation in Phase 2a and 2b trials for treatment-resistant depression and alcohol use disorder; RL-007, an orally bioavailable compound in Phase 2b for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a for major depressive disorder. Additional programs span various formulation types and mechanisms targeting similar indications.

The company also licenses marketed or in-development therapies, including COMP360 for psilocybin therapy and GRX-917 for anxiety, depression, and neurological disorders. The company operates across the United States, Germany, and Canada with a staff of 54 full-time employees and is headquartered in New York, New York. AtaiBeckley was incorporated in the Netherlands and is listed on Nasdaq. The company was previously known as Atai Beckley N.V. before changing its name to AtaiBeckley Inc. in December 2025.